Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Orforglipron in Obesity/Overweight with Knee Osteoarthritis (J2A-MC-GZPT)
jRCT2051250126Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of orforglipron in obesity, Overweight and knee osteoarthritis (OA) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in WOMAC Pain subscale score at Week 72. Started Nov 2025; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
obesityOverweightknee osteoarthritis (OA)
Beyond the preview
Go deeper on jRCT2051250126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250126.